Persistence to oral and injectable multiple sclerosis disease-modifying therapies

Multiple sclerosis is a chronic autoimmune disease that damages the central nervous system, with a diverse range of clinical symptoms and manifestation that is either episodic (relapsing-remitting) or progressive (primary or secondary). Prior research in Multiple Sclerosis has shown strong persistence to oral Disease-Modifying Therapies (DMT’s) compared with injectables, with medication possession ratios >85%.1 Given the increasing availability of oral DMT options, this study explores changes in real-world DMT adherence and persistence over time, across oral and injectable therapies. This study also explores differences in adherence and persistence for patients with progressive disease.